Comparison of Outcomes after Unrelated Double-Unit Cord Blood and Haploidentical Peripheral Blood Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia: A Study on Behalf of Eurocord and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

• Published in: Transplantation and cellular therapy Vol. 28; no. 10; pp. 710.e1 - 710.e10
• Main Authors: Ruggeri, Annalisa, Galimard, Jacques-Emmanuel, Labopin, Myriam, Rafii, Hanadi, Blaise, Didier, Ciceri, Fabio, Diez-Martin, Jose-Luiz, Cornelissen, Jan, Chevallier, Patrice, Sanchez-Guijo, Fermin, Nicholson, Emma, Castagna, Luca, Forcade, Edouard, Kuball, Jürgen, Rovira, Montserrat, Koc, Yener, Pavlu, Jiri, Gulbas, Zafar, Vydra, Jan, Baron, Frederic, Sanz, Jaime, Spyridonidis, Alexandros, Savani, Bipin, Gluckman, Eliane, Nagler, Arnon, Mohty, Mohamad
• Format: Journal Article Web Resource
• Language: English
• Published: Elsevier Inc 01.10.2022; Elsevier
• Subjects: 3A189DH42V (Alemtuzumab); 8N3DW7272P (Cyclophosphamide); Acute Disease; Acute myelogenous leukemia; Adult; Alemtuzumab; Antilymphocyte Serum; Bone Marrow; Cyclophosphamide/therapeutic use; Double cord blood transplantation; Fetal Blood; Graft vs Host Disease/prevention & control; Haploidentical transplant; Hematology; Human health sciences; Humans; Hématologie; Leukemia, Myeloid, Acute/therapy; Peripheral Blood Stem Cell Transplantation; Post-transplantation cyclophosphamide; Recurrence; Sciences de la santé humaine; Acute myelogenous leukemia; Haploidentical transplant; Double cord blood transplantation; Post-transplantation cyclophosphamide
• ISSN: 2666-6367; 2666-6375; 2666-6367
• DOI: 10.1016/j.jtct.2022.07.006

•Double umbilical cord blood transplantation and haploidentical post-transplantation cyclophosphamide with peripheral blood stem cell transplantation are useful strategies for treating adults with acute myelogenous leukemia in complete remission.•The conditioning regimen and graft-versus-host disease prophylaxis should be tailored to provide an antileukemia effect and prevent disease recurrence. Unmanipulated haploidentical hematopoietic stem cell transplantation (HCT) with post-transplantation cyclophosphamide as graft-versus-host disease (GVHD) prophylaxis (haplo-PTCY) and unrelated double-unit umbilical cord blood transplantation (dUCBT) are feasible options for treating patients with high-risk acute myelogenous leukemia (AML). This study compared outcomes after dUCBT and haplo-HCT using peripheral blood stem cells (PBSCs) in adult patients with AML in complete remission (CR) who underwent transplantation in European Society for Blood and Marrow Transplantation (EBMT)-affiliated centers. In a population of adults with de novo AML in first or second CR, we compared outcomes after dUCBT (n = 165) and after haplo-PTCY PBSC (n = 544) performed between January 2013 and December 2018. Patients receiving in vivo antithymocyte globulin, Campath, or ex vivo T cell depletion were excluded. The median follow-up was 33 months for the haplo-PTCY arm and 52 months for the dUCBT arm. No statistically significant differences were observed between the 2 arms in the rates of grade II-IV acute graft-versus-host disease (GVHD) (hazard ratio [HR], 1.31; P = .18), grade III-IV acute GVHD (HR, 1.17; P = .56), chronic GVHD (HR, .86; P = .48), relapse (HR, 1.07; P = .77), nonrelapse mortality (NRM) (HR, .94; P = .77), leukemia-free survival (LFS) (HR, .99; P = .95), or overall survival (OS) (HR, .99; P = .97). Favorable cytogenetic risk was the sole factor predictive of lower relapse incidence (RI). Younger age at transplantation was associated with lower NRM and higher LFS and OS. Both dUCBT and haplo-PTCY with PBSCs can be considered valid approaches for adult AML patients in CR. New strategies should be investigated in both settings to define the most appropriate conditioning regimen and potentially decrease RI and NRM through better immune reconstitution and optimal supportive care. [Display omitted]